Taliglucerase alfa: Difference between revisions
Content deleted Content added
m cat |
m Various citation cleanup, replaced: >http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652073/</ref> → >{{cite journal|pmc=2652073}}</ref> using AWB |
||
| Line 1: | Line 1: | ||
'''Taliglucerase alpha''' is a plant-derived enzyme that is currently (as of February 2011) in phase III clinical trials by Protalix and [[Pfizer]].<ref>http://clinicaltrials.gov/ct2/show/NCT00962260</ref> The enzyme is a recombinant [[glucocerebrosidase]] used to treat [[Gaucher's disease|Gaucher’s Disease]]. If it is approved by the U.S. [[Food and Drug Administration]] it will be first plant-made pharmaceutical.<ref>http://www.sciencemag.org/content/320/5875/473.summary</ref> Expression of proteins in plant cell culture is highly efficient, does not require post-expression modification of the protein, and is not susceptible to contamination by agents such as viruses that are pathological to humans.<ref>http://www.gaucherdisease.org/protalix_drug_information.php</ref> Using transgenic carrot cells produces a lower cost alternative, and preclinical studies show that the enzyme was well tolerated by patients.<ref> |
'''Taliglucerase alpha''' is a plant-derived enzyme that is currently (as of February 2011) in phase III clinical trials by Protalix and [[Pfizer]].<ref>http://clinicaltrials.gov/ct2/show/NCT00962260</ref> The enzyme is a recombinant [[glucocerebrosidase]] used to treat [[Gaucher's disease|Gaucher’s Disease]]. If it is approved by the U.S. [[Food and Drug Administration]] it will be first plant-made pharmaceutical.<ref>http://www.sciencemag.org/content/320/5875/473.summary</ref> Expression of proteins in plant cell culture is highly efficient, does not require post-expression modification of the protein, and is not susceptible to contamination by agents such as viruses that are pathological to humans.<ref>http://www.gaucherdisease.org/protalix_drug_information.php</ref> Using transgenic carrot cells produces a lower cost alternative, and preclinical studies show that the enzyme was well tolerated by patients.<ref>{{cite journal|pmc=2652073}}</ref> |
||
==References== |
==References== |
||
Revision as of 06:24, 22 August 2011
Taliglucerase alpha is a plant-derived enzyme that is currently (as of February 2011) in phase III clinical trials by Protalix and Pfizer.[1] The enzyme is a recombinant glucocerebrosidase used to treat Gaucher’s Disease. If it is approved by the U.S. Food and Drug Administration it will be first plant-made pharmaceutical.[2] Expression of proteins in plant cell culture is highly efficient, does not require post-expression modification of the protein, and is not susceptible to contamination by agents such as viruses that are pathological to humans.[3] Using transgenic carrot cells produces a lower cost alternative, and preclinical studies show that the enzyme was well tolerated by patients.[4]
References
- ^ http://clinicaltrials.gov/ct2/show/NCT00962260
- ^ http://www.sciencemag.org/content/320/5875/473.summary
- ^ http://www.gaucherdisease.org/protalix_drug_information.php
- ^ . PMC 2652073 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652073.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help)